Annual report pursuant to Section 13 and 15(d)

Stockholders' Deficit (Details 3)

v3.10.0.1
Stockholders' Deficit (Details 3) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Equity [Abstract]    
R&D Options Expense $ 52,452
Total research and development expenses 368,459 182,107
G&A PIU Issuance Expense 69,505
G&A Options Issuance Expense 199,451 135,891
Stock granted for Performance Bonus Plan Cancellation 1,461,545
Stock and warrants granted in IPO 3,436,406
Stock issued to consultants 218,500
Total general and administrative expenses 6,618,763 813,179
Total stock-based compensation expense $ 5,368,354 $ 205,396